Posted by Michael Wonder on 13 Jul 2022
NICE terminates appraisal of belimumab for new indication
13 July 2022 - You guessed it, the sponsor decided not to lodge an evidence submission.
NICE is unable to make a recommendation on the use of belimumab (Benlysta) for the treatment of patients with lupus nephritis because GlaxoSmithKline did not provide an evidence submission.
NICE will review this decision if GlaxoSmithKline decides to make a submission.
